Company profile for Landos Biopharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging our AI-based integrated computational platform, LANCE, we have identified seven novel clinical and preclinical candidates across various areas of unmet medical need. Our lead product candidate, BT-11, is a small molecule targeting Lanthion...
Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging our AI-based integrated computational platform, LANCE, we have identified seven novel clinical and preclinical candidates across various areas of unmet medical need. Our lead product candidate, BT-11, is a small molecule targeting Lanthionine Synthetase C-Like 2 (LANCL2), a pathway designed to limit its impact to the gastrointestinal tract. In January 2021, the Company reported initial results from its lead program.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1800 Kraft Drive, Suite 216 Blacksburg, VA 24060
Telephone
Telephone
(540) 218-2232
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-inks-immune-disorder-drug-licensing-deal-with-chinas-futuregen-2024-06-13/

REUTERS
14 Jun 2024

https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-buy-landos-expand-pipeline-immunity-related-illnesses-2024-03-25/

REUTERS
25 Mar 2024

https://www.businesswire.com/news/home/20240325259107/en

BUSINESSWIRE
25 Mar 2024

https://www.globenewswire.com/news-release/2024/03/21/2850157/0/en/Landos-Biopharma-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Results.html

GLOBENEWSWIRE
21 Mar 2024

https://ir.landosbiopharma.com/news-releases/news-release-details/landos-biopharma-present-new-data-immunometabolism-19th-annual

PRESS RELEASE
08 Mar 2024

https://www.globenewswire.com//news-release/2024/01/08/2805383/0/en/Landos-Biopharma-to-Present-New-Data-on-Immunometabolism-at-the-19th-Annual-Congress-of-the-European-Crohn-s-and-Colitis-Organisation.html

GLOBENEWSWIRE
08 Jan 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty